Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for 300171.SZ and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for 300171.SZ and 80,000+ other tickers.
See exactly how 300171.SZ's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 300171.SZ and 80,000+ other tickers.
Tofflon Science and Technology Group Co., Ltd., originally established in 1993 as Shanghai Tofflon Science and Technology Co., Ltd. and headquartered in Shanghai, China, serves as a global purveyor of sophisticated equipment for the pharmaceutical and biotechnology sectors. The company's diverse offerings encompass specialized machinery for injectable drug manufacturing, including automated systems for solution preparation, aseptic filling lines tailored for ampoules, vials, syringes, and powders, along with freeze dryers featuring automatic loading capabilities, barrier systems, and plastic…
No recent news available.